December 6, 2019 James Karrels Chief Financial Officer MacroGenics Inc. 9704 Medical Center Drive Rockville, Maryland 20850 Re: MacroGenics Inc. Form 10-K for the Fiscal Year Ended December 31, 2018 Filed February 26, 2019 File No. 001-36112 Dear Mr. Karrels: We have reviewed your filing and have the following comment. Please respond to this comment within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comment applies to your facts and circumstances, please tell us why in your response. After reviewing your response to this comment, we may have additional comments. Form 10-K for the Fiscal Year Ended December 31, 2018 Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations Strategic Collaborations Zai Lab, page 44 1. You state that ZaiLab would pay you double-digit royalties on annual net sales of the assets, which may be subject to adjustment in specified circumstances. Please confirm in future filings you will disclose the royalty rate or a range that does not exceed a 10 point range. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. You may contact Lisa Vanjoske at 202-551-3614 or Mary Mast at 202-551-3613 if you have questions regarding the comment. James Karrels MacroGenics Inc. December 6, 2019 Page 2 FirstName LastNameJames Karrels Sincerely, Comapany NameMacroGenics Inc. Division of Corporation Finance December 6, 2019 Page 2 Office of Life Sciences FirstName LastName